Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body’s immune system from acting in the presence of cancer.
Although checkpoint inhibitors hold immense promise for some patients, many fail to respond to treatment. Researchers are still trying to figure out why that may be – some hypothesizethat tumors littered with mutations, “hot” tumors, are more likely to respond to immunotherapy than tumors with fewer mutations, or “cold” tumors.
OncoSec Medical (NSDQ:ONCS) is betting that its electroporation technology can help convert cold tumors to hot ones, boosting the promised effects of immunotherapy for the cancer patients who have failed treatment with checkpoint inhibitors.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.